Education
About Us
Working with TipRanks
Follow Us
Comera Life Sciences Holdings (CMRA)
OTHER OTC:CMRA
CMRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $0.03
Previous CloseN/A
Volume4.00K
Average Volume (3M)1.76K
Market Cap
$6.15K
Enterprise Value$334.59K
Total Cash (Recent Filing)$1.77M
Total Debt (Recent Filing)$171.60K
Price to Earnings (P/E)―
Beta1614.16
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding30,737,797
10 Day Avg. Volume2,997
30 Day Avg. Volume1,763
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap54.42
Enterprise Value/Revenue0.09
Enterprise Value/Gross Profit0.45
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Comera Life Sciences Holdings News
PremiumCompany Announcements
Comera Life Sciences Faces Partnership and Acquisition Setbacks
PremiumCompany Announcements
Comera Life Sciences Announces Sweeping Workforce Termination
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.03% Other Institutional Investors
98.97% Public Companies and
Individual Investors
CMRA FAQ
What was Comera Life Sciences Holdings’s price range in the past 12 months?
Comera Life Sciences Holdings lowest stock price was $0.01 and its highest was $0.03 in the past 12 months.
What is Comera Life Sciences Holdings’s market cap?
Comera Life Sciences Holdings’s market cap is $6.15K.
When is Comera Life Sciences Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Comera Life Sciences Holdings’s earnings last quarter?
Currently, no data Available
Is Comera Life Sciences Holdings overvalued?
According to Wall Street analysts Comera Life Sciences Holdings’s price is currently Overvalued.
Does Comera Life Sciences Holdings pay dividends?
Comera Life Sciences Holdings does not currently pay dividends.
What is Comera Life Sciences Holdings’s EPS estimate?
Comera Life Sciences Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Comera Life Sciences Holdings have?
Comera Life Sciences Holdings has 30,737,797 shares outstanding.
What happened to Comera Life Sciences Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Comera Life Sciences Holdings?
Currently, no hedge funds are holding shares in CMRA
Company Description
Comera Life Sciences Holdings
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Salarius Pharmaceuticals
―
Hepion Pharmaceuticals
―
Windtree Therapeutics
―
ReShape Lifesciences
―
Universe Pharmaceuticals
―